Rubicon Research IPO Listing: Pharma Player Set for Strong Debut on October 16 – Key Highlights for Investors

Mumbai | October 15

All eyes are on Rubicon Research Ltd, the fast-growing pharmaceutical innovator, as it gears up for a blockbuster stock market debut on October 16, 2025. The ₹1,377.5-crore IPO — subscribed an extraordinary 104 times — has fuelled strong investor excitement, with shares set to list on both the NSE and BSE after overwhelming demand across categories. Here’s everything investors need to know — from subscription trends to GMP and financials.

Rubicon Research IPO: Listing Date and Issue Overview

The ₹1,377.5 crore Rubicon Research IPO is set to debut on Thursday, October 16, 2025, at 10 AM on both the NSE and BSE. The issue comprised a fresh equity share sale worth ₹500 crore and an Offer for Sale (OFS) of 1.81 crore shares aggregating to ₹877.5 crore by promoter General Atlantic Singapore RR Pte Ltd. The IPO allotment was finalised on October 14, with shares credited to successful investors’ Demat accounts on October 15.

Buzzing- Earnings Revival and Policy Stability to Power Markets in Samvat 2082: PL Capital Report

Investor Response: IPO Subscribed Over 100 Times

Investor enthusiasm for Rubicon Research was exceptional, with total bids exceeding 103.9 times the offer size — one of the strongest responses among recent pharma IPOs.

Rubicon Research IPO GMP Points to Strong Listing

According to grey market trackers, Rubicon Research’s GMP stands near ₹128, implying a 26% premium over the upper price band of ₹485. The ₹613 indicative price reflects strong investor confidence, though analysts caution that GMP is unregulated and may fluctuate ahead of listing.

Fund Utilisation and Growth Strategy

Proceeds from the issue will primarily go toward debt repayment, funding acquisitions, and general corporate purposes. The company said that listing would enhance visibility, strengthen brand value, and help create a public market for its equity shares.

Financial Snapshot: Profits Surge in FY25

Rubicon Research has posted stellar growth across revenue, assets, and profit in recent years, underscoring a sharp turnaround.

Market Outlook: Can Rubicon Deliver a Healthy Listing Pop?

Rubicon Research shares are currently commanding a premium in the grey market, trading nearly ₹96 above the issue price of ₹485. This suggests potential listing gains of around 20%, with reports from Investorgain pegging the unlisted share price near ₹612 — implying a ₹127 or 26% premium.

The strong Rubicon Research IPO GMP highlights sustained optimism around the company’s R&D-driven pharmaceutical portfolio, diversified customer base, and expanding global regulatory reach.

Disclaimer: The Grey Market Premium (GMP) is an unofficial indicator of investor sentiment and is not regulated by SEBI. It should not be considered the sole basis for investment decisions

Track the Listing Live

Rubicon Research lists on October 16 at 10 AM. Stay tuned with PL Capital for live market coverage, expert commentary, and real-time insights. Open your PL Capital Demat Account today to trade smarter this festive season. Visit https://instakyc.plindia.com/

Also Read- Rubicon Research IPO: Subscription Closes, Allotment Date & Listing Details